You are here:

MS in the media - 23 June 2017

Published on

17 - 23 June 2017

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

Smoking and progressive MS

Canadian research found that the time to EDSS levels for people with primary progressive MS was similar regardless of whether they had been smokers or not. This differs from previous research in people with replacing MS

Source: MS News Today

MS Trust link: Smoking

MRI scans and disability levels

American research found that about one in eight people had a mismatch between their level of disability and the number of lesions seen on an MRI scan - either low lesion load and high disability (more likely in people with progressive MS) or many lesions but low disability. Researchers speculate that this last group may have more cognitive issues

Source: MS News Today

MS Trust link: MRI scans

Suicide risk measured

Canadian review of previous studies of suicide in people with MS found the rate to be between 1.6 and 2.1 times that in the general population. Younger men within five years of diagnosis were at highest risk.

Source: Canadian MS Society

MS Trust link: Depression

European vaccine ruling

The European Court of Justice has ruled that vaccines can be considered the cause of subsequent illness even in the absence of any research evidence to support this. The case was prompted by someone in France who developed MS following a vaccination for hepatitis B

Source: News Medical
Source: Daily Telegraph

MS Trust link: Hepatitis B vaccine

Ocrevus and disease activity

Results to be presented at the European Academy of Neurology (EAN) meeting show that people with either relapsing or primary progressive MS taking Ocrevus (ocrelizumab) were more likely to maintain NEPAD over 96 weeks. NEPAD (an extended version of NEDA) indicates no relapses, no EDSS  progression, no new lesions on MRI, and no or small increases in measures of walking and dexterity.

Source: BusinessWire

MS Trust link: Ocrevus (ocrelizumab)

Print this page